ORKA

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2001, for Hyseq Pharmaceuticals, Inc. (d/b/a Hyseq, Inc.). The company is a biopharmaceutical firm focused on the research and development of novel therapeutic protein candidates derived from its proprietary gene discovery platform. As of the reporting date, the company had no commercial products on the market and relied on contract revenues and equity financing to fund operations.

Key Financial Metrics

Note: All figures are in thousands unless otherwise noted. The filing does not provide explicit gross margin percentages; however, operating expenses significantly exceeded revenues.

Material Changes vs. Prior Period

• Revenue Growth: Contract revenues for the nine months ended September 30, 2001, increased to $17.5 million from $11.3 million in the prior year period. This was primarily driven by the BASF collaboration, which reached full contractual capacity ($16.4 million for the nine months), compared to ramp-up periods in 2000.
• Expense Increases: Total operating expenses rose to $41.3 million for the nine months ended September 30, 2001, from $27.4 million in the prior year. Research and Development (R&D) expenses increased to $31.5 million due to expanded staffing, materials, and lease costs for new facilities. General and Administrative (G&A) expenses increased to $9.8 million, largely due to the addition of senior executives.
• Restructuring Charges: The company recorded a one-time restructuring charge of $0.8 million in the third quarter of 2001 for personnel and severance costs, associated with a reduction of approximately 50 employees.
• Liquidity Improvement: Cash and cash equivalents increased significantly from $2.7 million at December 31, 2000, to $16.5 million at September 30, 2001. This was driven by a private placement of equity and the drawdown of a line of credit.

Guidance, Outlook, and Risks

Management Commentary and Outlook: Management expects operating expenses to continue increasing as the company expands biopharmaceutical R&D. The company anticipates that existing capital resources and anticipated cash from collaborations will support operations through the third quarter of 2002. However, management explicitly states the need to secure additional financing prior to that time to fund facility build-outs and expanded research. Failure to obtain adequate financing could force the company to delay or eliminate development programs.

Subsequent Events and Strategic Shifts (October 2001):

• Affymetrix Settlement: The company settled all litigation with Affymetrix, Inc. This included a $4 million loan from Affymetrix and a collaboration to develop a high-speed DNA sequencing chip via a new subsidiary, Callida Genomics, Inc.
• Reorganization: The company plans to reorganize into two entities: Hyseq Pharmaceuticals, Inc. (biopharmaceuticals) and Callida Genomics, Inc. (sequencing technology).
• New Collaborations: Announced a collaboration with Deltagen, Inc. to research novel secreted proteins and a research collaboration with Kirin Brewery Co., Ltd.

Risks and Contingencies:

• Financing Risk: The company has a history of operating losses and an accumulated deficit of $97.0 million. It requires substantial additional capital to reach commercialization.
• Regulatory and Development Risk: No products are in clinical trials; all candidates are in research or preclinical stages. Success is not guaranteed, and regulatory approval is uncertain.
• Dependency on Partners: Revenue and development progress are heavily dependent on the performance and funding of strategic partners (e.g., BASF, Chiron, Kirin).
• Market Risk: The company faces intense competition and potential volatility in stock price due to its pre-revenue status and reliance on equity markets.

Investor Verification Checklist

• Capital Runway: Verify the sufficiency of the $16.5 million cash balance against the projected burn rate and the timeline for securing the "additional funding" required before Q3 2002.
• Collaboration Terms: Review the specific milestone and royalty terms of the BASF agreement (1.5 years remaining) and the new Affymetrix/Deltagen/Kirin collaborations to assess future revenue visibility.
• Restructuring Impact: Confirm the realization of the projected $3.8 million annualized savings from the recent workforce reduction.
• Legal Settlement Details: Examine the terms of the Affymetrix settlement, specifically the $4 million loan repayment schedule and the equity structure of the new Callida Genomics subsidiary.
• Facility Leases: Assess the financial impact of the new 138,698 square foot lease in Sunnyvale, which totals approximately $54.1 million over ten years.